Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
CRISPR/Cas therapeutic strategies for autosomal dominant disorders
Salvatore Marco Caruso, … , Bruna Lopes da Costa, Stephen H. Tsang
Salvatore Marco Caruso, … , Bruna Lopes da Costa, Stephen H. Tsang
Published May 2, 2022
Citation Information: J Clin Invest. 2022;132(9):e158287. https://doi.org/10.1172/JCI158287.
View: Text | PDF
Review

CRISPR/Cas therapeutic strategies for autosomal dominant disorders

  • Text
  • PDF
Abstract

Autosomal dominant disorders present unique challenges, as therapeutics must often distinguish between healthy and diseased alleles while maintaining high efficiency, specificity, and safety. For this task, CRISPR/Cas remains particularly promising. Various CRISPR/Cas systems, like homology-directed repair, base editors, and prime editors, have been demonstrated to selectively edit mutant alleles either by incorporating these mutations into sgRNA sequences (near the protospacer-adjacent motif [“near the PAM”]) or by targeting a novel PAM generated by the mutation (“in the PAM”). However, these probability-based designs are not always assured, necessitating generalized, mutation-agnostic strategies like ablate-and-replace and single-nucleotide polymorphism editing. Here, we detail recent advancements in CRISPR therapeutics to treat a wide range of autosomal dominant disorders and discuss how they are altering the landscape for future therapies.

Authors

Salvatore Marco Caruso, Peter M.J. Quinn, Bruna Lopes da Costa, Stephen H. Tsang

×

Figure 2

Mechanism of prime editing.

Options: View larger image (or click on image) Download as PowerPoint
Mechanism of prime editing.
Schematic detailing critical steps of prime ...
Schematic detailing critical steps of prime editing mechanism of action broken down by Cas9 activity, RT activation and function, stochastic endogenous repair mechanisms, and potential editing outcomes. (i) Protospacer hybridization between pegRNA and target DNA sequence. (ii) Engineered SpCas9 creates single-strand break in strand opposite pegRNA hybridization. (iii) Hybridization between the protospacer binding sequence (PBS) of pegRNA and newly generated 3′ flap from nickase activity. (iv) Reverse transcriptase adds nucleotides to the new 3′ end of the nicked DNA strand as directed by reverse transcription template (RTT) found adjacent to the PBS sequence. (v) An equilibrium is achieved between the unedited and edited flaps, where only one is reinserted back into DNA via endogenous DNA repair mechanisms. (vi) Insertion of 3′ flap back into the DNA and pruning of the 5′ flap by exonucleases results in the formation of a heteroduplex, where mismatch repair mechanisms determine whether the unedited strand will be remodeled in response to the edit, or whether the edit will be undone with the unedited strand as template. This process can be shifted in favor of incorporating the edit by introducing an sgRNA that nicks the unedited strand, increasing mismatch repair and improving editing efficiencies. Adapted from da Costa et al. (30).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts